Biopharmaceutical firm GTx has entered into a merger agreement with clinical-stage biotechnology firm Oncternal Therapeutics to create a new a publicly-traded and clinical-stage oncology company.
Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, announced the successful completion of a $135m Series B financing.
GeoVax Labs, a biotechnology company developing human vaccines, has expanded its collaboration activities with Leidos, to develop malaria vaccine candidates.
American multinational biotechnology company Biogen has agreed to acquire UK-based clinical-stage gene therapy firm Nightstar Therapeutics in a deal valued at around $877m.
Abpro, a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases, and NJCTTQ, a global pharmaceutical company, have entered into an agreement to develop multiple novel bispecific antibody therapies in immuno-oncology, including best-in -class T-cell engagers.
Third Rock Ventures, a healthcare venture firm focused on disruptive areas of science and medicine, has launched Maze Therapeutics to focus on translating genetic insights into new medicines.
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative and neuropsychiatric diseases, announced the completion of a $25m series B equity financing.
Novartis and Blackstone Life Sciences have launched new biopharmaceutical firm, dubbed Anthos Therapeutics, to develop new medicines for cardiovascular disease.
Imbrium Therapeutics, a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, and TetraGenetics, a biotech company developing novel therapeutics for pain indications and autoimmune diseases, announced a strategic research & development collaboration to utilize TetraGenetics’ antibody discovery technology platform (TetraExpress) in the discovery and development of non-opioid biologic therapies for the treatment of chronic pain.
Novartis announced that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.